Navigation Links
LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis

LegalView recently posted detailed information on its Cimzia information portal regarding the potentially serious side effects caused by the drug and its family known as TNF inhibitors. Among the drug's potential side effects are the development of fatal infections and cancer-causing agents for young adult and child patients.

Denver, CO (PRWEB) October 6, 2008 -- LegalView, the number one resource for everything and anything legal on the Internet, informed arthritis and Crohn's disease patients about the potentially fatal dangers posed by a group of prescription drugs known as TNF blockers. The drugs, which include Cimzia, Humira, Enbrel and Remicade, are all categorized as tumor necrosis factor (TNF) inhibitors that act as immunosuppressors to decrease the pain in patients suffering from rheumatoid or juvenile arthritis as well as Crohn's disease, which is a severe inflammation of the gastrointestinal (GI) tract.

One of the TNF blockers is the drug known as Remicade (infliximabe) from Johnson & Johnson, which was approved in 1999. The drug treats psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, sarcoidosis and ulcerative colitis. The potential [Remicade side effects __title__ Remicade Risks] associated with taking the drug can include the development of blood disorders (some of which have been deemed fatal) allergic reactions, reactivation of hepatitis B and the potential for developing lymphoma, according to the company.

Humira, from Abbott Laboratories, was introduced for use only a few years ago in 2002. Patients taking Humira -- also approved to treat rheumatoid/psoriatic arthritis, Crohn's disease, psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis -- should speak to a medical professional immediately if they are showing any signs of the potential [Humira side effects __title__ Humira Class Action] that can occur among those who consume the drug. These can include jaundice, weakness, confusion, seizure, shortness of breath and a burning sensation during urination.

Enbrel (etanercept) is manufactured by Amgen and Wyeth and was released for market use in 1998. The drug has been approved to treat an array of conditions including severe rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. In addition to the potential for causing possibly fatal infections, the [Enbrel side effects __title__ Enbrel Lawsuit] can range from a dry cough to fever, shortness of breath, swollen glands, muscle aches and chest pain, vomiting/nausea or seizures.

Of the TNF inhibitors, Cimzia is the most recent to be approved for use, approved in 2008. Cimzia (certolizumab pegol) is from makers UCB and was approved for treating Crohn's disease, which affects more than half a million Americans currently. Individuals who have taken Cimzia and are at potential risk for developing fatal infection or cancer, should contact a medical professional immediately and will likely need to discontinue use of the drug. Patients may also need further information on developing a potential [Cimzia class action __title__ Cimzia Lawyer] lawsuit in case monetary compensation is needed to pay for the medical bills associated with the [Cimzia side effects __title__ Cimzia Dangers]. If this occurs, contacting an experienced [Cimzia attorney __title__ Cimzia Law Firm] who can provide a free legal consultation may be necessary.

In addition to providing legal information about the severe medical risks associated with the TNF blockers, LegalView also recently updated two of its information portals to provide victims of both mesothelioma cancer and truck accidents relief by offering articles, jury verdicts and treatments on coping with their recent misfortune.

Mesothelioma victims can visit the [mesothelioma blog __title__ Mesothelioma Information] to read about the latest news updated several times a week offering tips on how to participate in clinical trials, as well as the latest treatment available.

For [truck accident victims __title__ Truck Accident Lawsuit], LegalView provides the latest statistics on commercial truck accidents, considered the most costly and fatal of all vehicular accidents, as well as how to obtain a truck accident attorney.

About LegalView: is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
2. LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients
3. LegalView Brain Injury Site Reports Department of Veteran Affairs Request for Research on TBI and Soldiers
4. LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI
5. LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years
6. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
7. LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents
8. LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition
9. Nasdaq Informs Synutra that the Companys Filing Delinquency has been Cured
10. Math battling cancer, deciding lifes challenges lead list as INFORMS meet in Seattle
11. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
(Date:11/30/2015)... ... 30, 2015 , ... SIMmersion’s ability to present dynamic scenarios ... of the future. To reach an audience of key visionaries and reformers in ... Chicago, organized by the American Medical Association. , AMA President Steven Stack, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that it has ... competencies in the Application Development, demonstrating a “best-in-class” ability and commitment to ...
(Date:11/30/2015)... November 30, 2015 (PRWEB) , ... ... ... and Winscribe are pleased to announce their strategic partnership at the Radiological ... consultants, SpeechCheck, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
Breaking Medicine Technology: